Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma

Università degli Studi di Ferrara

Status and phase: Completed; Phase 3

Conditions: Asthma

Treatments: Drug: terbutaline; Drug: budesonide/formoterol combination (PRN); Drug: placebo; Drug: budesonide/formoterol combination

Study type: Interventional

Funder types: Other

Identifiers

NCT00849095

AIFA-ASMA-BF-001

EudraCT number: 2008-004127-36 (Registry Identifier)

Details and patient eligibility

About

Study No.001 about Budesonide/Formoterol use in ASthMA sponsored by Agenzia Italiana del FArmaco (Italian Drug Agency) (AIFA-ASMA-BF-001) The aim of the study is to verify whether asthma not controlled by low doses inhaled corticosteroids, thus in need for step up therapy, can be equally controlled by guidelines recommended regular bid treatment with long acting beta agonist/inhaled corticosteroid (ICS/LABA) combination or the symptom driven use of an ICS/LABA combination in the absence of maintenance therapy. The study is designed to be able to evaluate the non inferiority of regular placebo plus prn inhaled budesonide/formoterol (experimental treatment) versus regular, twice daily 160/4.5 mcg inhaled budesonide/formoterol combination plus prn inhaled terbutaline (guidelines recommended treatment).

Full description

Asthma is a problem worldwide, with an estimated 300 million affected individuals.There is evidence that asthma prevalence has been increasing in the last decades in some countries, including Italy. Analyses of the cost of asthma lead to conclude that the burden of the disease depend on the extent to which exacerbations are avoided since emergency treatment is more expensive than regular treatment.

Based on solid evidence, international guidelines recommend regular treatment with low dose ICS for mild persistent asthma and treatment with combination therapy [low dose ICS plus long-acting beta2-agonists (LABA)] for patients with asthma not controlled by low doses ICS alone. Recent studies have undermined the axiom that treatment with ICS must be regular to achieve and maintain asthma control, as equivalent control has been obtained either with prn use of an inhaled combination of a short acting beta2 agonist (SABA) and an ICS, or with a short course of 10 days high dose ICS at the start of exacerbations. In moderate-severe asthma regularly treated with inhaled ICS/LABA combination, the symptom-driven use of the same inhaled ICS/LABA combination as reliever is superior to the symptom-driven use of SABA or LABA alone.

Enrollment: 860 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female out-patient aged from 18 years to 65 years
• Clinical diagnosis of moderate persistent asthma for at least 6 months, according to GINA revised version 2006 guidelines
• Post-bronchodilator forced expiratory volume (FEV1) at least 80% of the predicted
• Either positive methacholine challenge test (PC20 FEV1< 4mg/ml or PD20 FEV1<0.8 mg) or positive response to the reversibility test in the last year
• Asthma either not adequately controlled with low-dose (≤500 mcg beclomethasone or equivalent) inhaled corticosteroids (ICS) or controlled by bid inhaled combination of low-dose ICS/long acting beta-2 agonists (LABA)
• A co-operative attitude and ability to be trained to correctly use the dry powder inhalator and to complete the diary cards
• Written informed consent obtained

Exclusion criteria

• Inability to carry out pulmonary function testing
• Moderate severe asthma associated with reduced lung function
• History of near-fatal asthma and/or admission intensive care unit because of asthma
• 3 or more courses of oral corticosteroids or hospitalization for asthma during the previous year
• Diagnosis of COPD as defined by the GOLD guidelines
• Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 8 weeks
• Current smokers or recent (less than one year) ex-smokers, defined as smoking at least 10 pack/years
• History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe hypertension, or cardiac arrhythmias
• Diabetes mellitis
• Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) during the previous six months
• Abnormal ECG
• Clinically significant or unstable concurrent diseases: uncontrolled hyperthyroidism, significant hepatic impairment, poorly controlled pulmonary disease (tuberculosis, active mycotic infection of the lung), gastrointestinal (e.g., active peptic ulcer), neurological or haematological autoimmune diseases
• Malignancy
• Any chronic diseases with prognosis < 2 years
• Pregnant or lactating females or not able to exclude pregnancy during the study period
• History of alcohol or drug abuse
• Patients treated with monoamine oxidase inhibitors, tricyclic antidepressants or beta-blockers as regular use
• Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients
• Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study
• Patients who received any investigational new drug within the last 12 weeks
• Patients who have been previously enrolled in this study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

860 participants in 2 patient groups

as needed medication

Experimental group

Description:

patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination

Treatment:

Drug: budesonide/formoterol combination (PRN)

Drug: placebo

guideline treatment

Active Comparator group

Description:

bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline

Treatment:

Drug: budesonide/formoterol combination

Drug: terbutaline